DUBLIN--(BUSINESS WIRE)--Sep 3, 2018--The "Global Personalised Medicine Market - Technologies, Market share and Industry Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.

Global personalized medicine market is expected to rise with a CAGR of 12% over the forecast period 2017-2024.

Key factors driving the market growth are rising prevalence of cancer, development of novel drugs, growth in biotechnology sector and growing number of companion/associated diagnostics.

Stringent government regulations regarding product approval and high development costs are expected to restrain the market growth. However, increasing healthcare expenditure and favorable government policies and initiatives are expected to provide lucrative market opportunities.

Complex nature of the drugs and presence of non-value based personalized medicine diagnostics reimbursement policy is expected to challenge the market growth.

Key Highlights

On the basis of therapeutic area, neurology is the leading therapeutic area segment owing to the increase in research and development activities for the development of novel precision medicines for the cost-effective treatment of neurological disorders. On the basis of end-user, hospitals is the dominating end-user segment due to the increased adoption of personalized medicines by the hospital patients for low cost personalized treatment. On the basis of applications, biomarker identification is the leading application segment due to increased adoption of personalized medicines for the identification genes specific to the disease subtypes which would assist in the estimation of disease risk and therapy response.

Key Topics Covered

1. Introduction

2. Market Overview

3. Market Determinants

4. Global Personalized Medicine Market, by Therapeutic Area

5. Global Personalized Medicine Market, by End-User

6. Global Personalized Medicine Market, by Application

7. Competitive Landscape

8. Geographic Analysis

9. Company Profiles

Abbott Laboratories (U.S.) Astra Zeneca PLC (UK) Asuragen Incorporated (UK) Becton, Dickinson and Company (U.S.) Biogen Inc. (U.S.) GE Healthcare (U.S.) Glaxosmithkline PLC (UK) Illumina Incorporated (U.S.) Merck & Company Inc. (U.S.) Novartis AG (Switzerland) Pfizer Inc. (U.S.) Qiagen Inc. (The Netherlands) Roche Holding AG (Switzerland) Siemens Healthcare (Germany) Vertex Pharmaceuticals Inc. (UK)

For more information about this report visit https://www.researchandmarkets.com/research/qpx4zn/personalised?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180903005080/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Genomics

KEYWORD:

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/03/2018 05:36 AM/DISC: 09/03/2018 05:36 AM

http://www.businesswire.com/news/home/20180903005080/en